https://orcid.org/0000-0003-1812-9104
References
- Brink CB, Harvey BH, Brand L. Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. Recent Pat CNS Drug Discov. 2006;1(1):29–41.
- Sacchetti G, Bonini I, Waeterloos GC, et al. Tianeptine raises dopamine and blocks stress-induced noradrenaline release in the rat frontal cortex. Eur J Pharmacol. 1993;236(2):171–175.
- Gassaway MM, Rives ML, Kruegel AC, et al. The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist. Transl Psychiatry. 2014;4(7):e411.
- El Zahran T, Schier J, Glidden E, et al. Characteristics of tianeptine exposures reported to the National Poison Data System - United States, 2000-2017. MMWR Morb Mortal Wkly Rep. 2018;67(30):815–818.
- Bakota EL, Samms WC, Gray TR, et al. Case reports of fatalities involving tianeptine in the United States. J Anal Toxicol. 2018;42(7):503–509.
- Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(1):S31–S34.
- Marraffa JM, Stork CM, Hoffman RS, et al. Poison control center experience with tianeptine: an unregulated pharmaceutical product with potential for abuse. Clin Toxicol. 2018;56(11):1155–1158.
- Murphy C, Dulaney A, Laes J. Tianeptine: a review of cases reported to one US regional poison center. Clin Toxicol, 2019;57(10):870–1052.
- Durmus N, Ozbilen G, Kasap Y, et al. Risk management in tianeptine abuse in Turkey: a national experience. Klinik Psikofarmakoloji Bülteni [Bull Clin Psychopharmacol]. 2013;23(2):149–154.
- Lauhan R, Hsu A, Alam A, et al. Tianeptine abuse and dependence: case report and literature review. Psychosomatics. 2018;59(6):547–553.
- Salvadori C, Ward C, Defrance R, et al. The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans-influence of alcohol co-administration. Fundam Clin Pharmacol. 1990;4(1):115–125.